Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel. more
Time Frame | ENLV | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.33% | -2.74% | -3% |
1-Month Return | 27.05% | 0.59% | -0.73% |
3-Month Return | -17.88% | 4.48% | 2.87% |
6-Month Return | -6.28% | 1.61% | 7.17% |
1-Year Return | -36.57% | 22.58% | 25.31% |
3-Year Return | -80.38% | 40.42% | 28.38% |
5-Year Return | -87.39% | 155.62% | 81.89% |
10-Year Return | -99.5% | 452.63% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 2.28M | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 297.00K | 286.00K | 546.00K | 777.00K | 835.00K | [{"date":"2019-12-31","value":35.57,"profit":true},{"date":"2020-12-31","value":34.25,"profit":true},{"date":"2021-12-31","value":65.39,"profit":true},{"date":"2022-12-31","value":93.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (297.00K) | 1.99M | (546.00K) | (777.00K) | (835.00K) | [{"date":"2019-12-31","value":-14.92,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-27.42,"profit":false},{"date":"2022-12-31","value":-39.03,"profit":false},{"date":"2023-12-31","value":-41.94,"profit":false}] |
Gross Margin | (Infinity%) | 87.44% | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 8.62M | 9.79M | 19.29M | 25.80M | 29.39M | [{"date":"2019-12-31","value":29.32,"profit":true},{"date":"2020-12-31","value":33.29,"profit":true},{"date":"2021-12-31","value":65.62,"profit":true},{"date":"2022-12-31","value":87.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (8.62M) | (9.79M) | (19.29M) | (25.80M) | (29.39M) | [{"date":"2019-12-31","value":-861900000,"profit":false},{"date":"2020-12-31","value":-978500000,"profit":false},{"date":"2021-12-31","value":-1928800000,"profit":false},{"date":"2022-12-31","value":-2579700000,"profit":false},{"date":"2023-12-31","value":-2939500000,"profit":false}] |
Total Non-Operating Income/Expense | (534.00K) | (1.82M) | 4.61M | (4.44M) | 1.88M | [{"date":"2019-12-31","value":-11.58,"profit":false},{"date":"2020-12-31","value":-39.46,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-96.31,"profit":false},{"date":"2023-12-31","value":40.72,"profit":true}] |
Pre-Tax Income | (9.38M) | (11.82M) | (14.47M) | (31.06M) | (29.07M) | [{"date":"2019-12-31","value":-938400000,"profit":false},{"date":"2020-12-31","value":-1182400000,"profit":false},{"date":"2021-12-31","value":-1446800000,"profit":false},{"date":"2022-12-31","value":-3106000000,"profit":false},{"date":"2023-12-31","value":-2906800000,"profit":false}] |
Income Taxes | 765.00K | 2.04M | (4.82M) | 11.35M | 4.24M | [{"date":"2019-12-31","value":6.74,"profit":true},{"date":"2020-12-31","value":17.97,"profit":true},{"date":"2021-12-31","value":-42.48,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":37.4,"profit":true}] |
Income After Taxes | (10.15M) | (13.86M) | (9.65M) | (42.41M) | (33.31M) | [{"date":"2019-12-31","value":-1014900000,"profit":false},{"date":"2020-12-31","value":-1386300000,"profit":false},{"date":"2021-12-31","value":-964800000,"profit":false},{"date":"2022-12-31","value":-4240700000,"profit":false},{"date":"2023-12-31","value":-3331200000,"profit":false}] |
Income From Continuous Operations | (9.38M) | (11.82M) | (14.47M) | (31.06M) | (27.16M) | [{"date":"2019-12-31","value":-938400000,"profit":false},{"date":"2020-12-31","value":-1182400000,"profit":false},{"date":"2021-12-31","value":-1446800000,"profit":false},{"date":"2022-12-31","value":-3106000000,"profit":false},{"date":"2023-12-31","value":-2716200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (10.15M) | (13.86M) | (9.65M) | (42.41M) | (29.07M) | [{"date":"2019-12-31","value":-1014900000,"profit":false},{"date":"2020-12-31","value":-1386300000,"profit":false},{"date":"2021-12-31","value":-964800000,"profit":false},{"date":"2022-12-31","value":-4240700000,"profit":false},{"date":"2023-12-31","value":-2906800000,"profit":false}] |
EPS (Diluted) | (0.81) | (0.71) | - | (2.24) | (1.59) | [{"date":"2019-12-31","value":-81,"profit":false},{"date":"2020-12-31","value":-71,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-224,"profit":false},{"date":"2023-12-31","value":-159,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ENLV | |
---|---|
Cash Ratio | 8.78 |
Current Ratio | 9.71 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ENLV | |
---|---|
ROA (LTM) | -27.46% |
ROE (LTM) | -61.17% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ENLV | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.89 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ENLV | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.03 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Enlivex Therapeutics Ltd (ENLV) share price today is $1.24
Yes, Indians can buy shares of Enlivex Therapeutics Ltd (ENLV) on Vested. To buy Enlivex Therapeutics Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ENLV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Enlivex Therapeutics Ltd (ENLV) via the Vested app. You can start investing in Enlivex Therapeutics Ltd (ENLV) with a minimum investment of $1.
You can invest in shares of Enlivex Therapeutics Ltd (ENLV) via Vested in three simple steps:
The 52-week high price of Enlivex Therapeutics Ltd (ENLV) is $4.59. The 52-week low price of Enlivex Therapeutics Ltd (ENLV) is $0.81.
The price-to-earnings (P/E) ratio of Enlivex Therapeutics Ltd (ENLV) is
The price-to-book (P/B) ratio of Enlivex Therapeutics Ltd (ENLV) is 1.03
The dividend yield of Enlivex Therapeutics Ltd (ENLV) is 0.00%
The market capitalization of Enlivex Therapeutics Ltd (ENLV) is $25.95M
The stock symbol (or ticker) of Enlivex Therapeutics Ltd is ENLV